Kiniksa reports Q4 net income $4.5M vs loss; ARCALYST revenue $122.5M in FY2022

Kiniksa Pharmaceuticals International, plc

2022-FY EPS reported $2.60 revenue$220,180,000

ARCALYST net product revenue $39.9M in Q4, $122.5M full-year 2022; FY2023 guidance $190-205M.
Total revenue $61.9M Q4, $220.2M full-year; license revenue from Roche/Genentech and Huadong.
Net income $4.5M Q4 vs loss $36.3M; full-year net income $183.4M includes $172.3M tax benefit.
Cash $190.6M, no debt; expects cash to fund operations into at least 2025.
KPL-404 Phase 2 RA trial advancing; efficacy data expected first half 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.92

Kiniksa Pharmaceuticals International, plc reported the fiscal year ended December 31, 2022 results: revenue Total revenue for the full-year 2022 was $220.2 million, net income Net income for the full-year 2022 was $183.4 million. Guidance reaffirmed.

Period: the fiscal year ended December 31, 2022
Revenue: Total revenue for the full-year 2022 was $220.2 million
Net income: Net income for the full-year 2022 was $183.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On February 28, 2023, Kiniksa Pharmaceuticals, Ltd. issued a press release announcing financial results for the fiscal year ended December 31, 2022.

View on SEC.gov

Browse all earnings releases →

Kiniksa Pharmaceuticals International, plc filing history →

Source: SEC EDGAR

accession 0001104659-23-026402

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.